within Pharmacolibrary.Drugs.ATC.N;

model N07BC04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.72,
    Cl             = 0.0005,
    adminDuration  = 600,
    adminMass      = 0.2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.018333333333333333,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N07BC04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Lofexidine is a centrally acting alpha-2 adrenergic receptor agonist used primarily to manage symptoms of opioid withdrawal. It reduces the release of norepinephrine and is approved for clinical use in opioid detoxification. Lofexidine is currently approved in several countries, including the United States and the United Kingdom, for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers following single oral administration.</p><h4>References</h4><ol><li><p>Al Ghananeem, AM, Herman, BH, Abbassi, M, Yu, E, Miotto, K, O&#x27;Brien, CP, Ling, W, Montgomery, A, &amp; Walsh, R (2009). Urine and plasma pharmacokinetics of lofexidine after oral delivery in opiate-dependent patients. <i>The American journal of drug and alcohol abuse</i> 35(5) 311–315. DOI:<a href=&quot;https://doi.org/10.1080/00952990903060135&quot;>10.1080/00952990903060135</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19637105/&quot;>https://pubmed.ncbi.nlm.nih.gov/19637105</a></p></li><li><p>Al-Ghananeem, AM (2009). Pharmacokinetics of lofexidine hydrochloride in healthy volunteers. <i>Journal of pharmaceutical sciences</i> 98(1) 319–326. DOI:<a href=&quot;https://doi.org/10.1002/jps.21401&quot;>10.1002/jps.21401</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18393298/&quot;>https://pubmed.ncbi.nlm.nih.gov/18393298</a></p></li><li><p>Yu, E, Miotto, K, Akerele, E, O&#x27;Brien, CP, Ling, W, Kleber, H, Fischman, MW, Elkashef, A, Herman, BH, &amp; Al-Ghananeem, AM (2008). Clinical pharmacokinetics of lofexidine, the alpha 2-adrenergic receptor agonist, in opiate addicts plasma using a highly sensitive liquid chromatography tandem mass spectrometric analysis. <i>The American journal of drug and alcohol abuse</i> 34(5) 611–616. DOI:<a href=&quot;https://doi.org/10.1080/00952990802308122&quot;>10.1080/00952990802308122</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18821454/&quot;>https://pubmed.ncbi.nlm.nih.gov/18821454</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N07BC04;
